PRA Health Sciences
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
(Learn how and when to remove this template message)
|
 PRA Health Sciences logo 2014 | |
| Public | |
| Traded as | |
| ISIN | US69354M1080  |
| Industry | Pharmaceuticals & Biotechnology |
| Founded | 1976 Charlottesville, Virginia, U.S. |
| Headquarters | , U.S. |
Area served | Worldwide |
Key people | Colin Shannon (President and CEO) |
| Revenue | |
Number of employees | 17,000+[1] |
| Website | prahs |
US$ 1.948 billion (2017)PRA Health Sciences is a contract research organization (CRO) with headquarters in Raleigh, North Carolina that was founded in 1982.[2] In 2013 the company was acquired by Kohlberg Kravis Roberts, which brought the company public in November 2014 and maintained shares until September 2019.[3]
In August 2017 the company acquired Conshohocken-based real-world healthcare data, analytics, and technology solutions company Symphony Health for US$530 million.[4]
In November 2019 PRA announced it was partnering with Johnson & Johnson pharmaceutical arm Janssen Pharmaceutica in a first-of-its-kind decentralized clinical trial evaluating the drug Invokana (canagliflozin) in adults with heart failure, with preserved or reduced ejection fraction, with or without type 2 diabetes. This landmark study will collect real-world evidence via a mobile clinical trial platform. [5]
PRA's 2018 revenue was US$2.87 billion.[6]
References[edit]
- ^ a b c "PRA 10-K For the fiscal year ended December 31, 2017". PRA Health Sciences via SEC Edgar. 2018-02-02. See SEC Edgar index page for PRA for updates
- ^ "PRA Health Sciences becomes latest big CRO to launch IPO". CenterWatch News Online. 13 November 2014.
- ^ "PRA Health Sciences Announces Secondary Offering and Concurrent Share Repurchase". Globenewswire. September 3, 2019.
- ^ Liu, Angus (August 8, 2017). "PRA Health Sciences makes $530M Symphony buy, reports 16% revenue growth in Q2". FierceBiotech.
- ^ "AHA: Janssen drops clinical sites for smartphones, wearables in 100% virtual Invokana study". FierceBiotech. November 16, 2019.
- ^ https://investor.prahs.com/static-files/06f80501-79f0-4108-a719-1c54796903ba
